Senseonics Holdings, Inc. Common Stock (NASDAQ:SENS) Given New $18.00 Price Target at Mizuho

Senseonics Holdings, Inc. Common Stock (NASDAQ:SENS) had its price target cut by Mizuho from $20.00 to $18.00 in a research note published on Wednesday morning,Benzinga reports. They currently have an outperform rating on the stock.

Several other equities research analysts have also weighed in on the company. HC Wainwright reduced their price objective on Senseonics Holdings, Inc. Common Stock from $18.50 to $14.00 and set a “buy” rating for the company in a research note on Tuesday, May 12th. Stifel Nicolaus reduced their target price on Senseonics Holdings, Inc. Common Stock from $9.00 to $8.00 and set a “hold” rating for the company in a report on Monday, May 11th. Finally, Weiss Ratings lowered Senseonics Holdings, Inc. Common Stock from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, May 28th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $17.20.

Senseonics Holdings, Inc. Common Stock Stock Up 2.4%

Shares of SENS stock opened at $5.15 on Wednesday. The company’s 50-day moving average price is $6.11. The company has a market capitalization of $215.29 million, a PE ratio of -2.58 and a beta of 0.99. Senseonics Holdings, Inc. Common Stock has a fifty-two week low of $4.79 and a fifty-two week high of $12.58. The company has a debt-to-equity ratio of 1.05, a current ratio of 3.51 and a quick ratio of 3.19.

Senseonics Holdings, Inc. Common Stock (NASDAQ:SENS) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($0.71) earnings per share for the quarter, missing the consensus estimate of ($0.65) by ($0.06). The business had revenue of $11.71 million for the quarter. Senseonics Holdings, Inc. Common Stock had a negative net margin of 213.87% and a negative return on equity of 129.97%. On average, sell-side analysts anticipate that Senseonics Holdings, Inc. Common Stock will post -2.38 earnings per share for the current year.

Insider Buying and Selling at Senseonics Holdings, Inc. Common Stock

In other Senseonics Holdings, Inc. Common Stock news, Director Douglas A. Roeder purchased 22,686 shares of the firm’s stock in a transaction on Tuesday, May 12th. The shares were purchased at an average price of $5.56 per share, for a total transaction of $126,134.16. Following the completion of the purchase, the director directly owned 144,635 shares of the company’s stock, valued at approximately $804,170.60. This represents a 18.60% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 4.70% of the company’s stock.

Institutional Investors Weigh In On Senseonics Holdings, Inc. Common Stock

Hedge funds and other institutional investors have recently made changes to their positions in the company. Kestra Advisory Services LLC acquired a new position in shares of Senseonics Holdings, Inc. Common Stock in the 1st quarter valued at $68,000. GSK plc acquired a new position in Senseonics Holdings, Inc. Common Stock during the fourth quarter worth $60,000. Townsend Asset Management Corp NC ADV bought a new position in shares of Senseonics Holdings, Inc. Common Stock in the 4th quarter valued at about $60,000. Cetera Investment Advisers acquired a new position in shares of Senseonics Holdings, Inc. Common Stock during the 1st quarter worth approximately $85,000. Finally, Sanctuary Advisors LLC bought a new stake in Senseonics Holdings, Inc. Common Stock during the fourth quarter worth $71,000. 12.36% of the stock is owned by institutional investors and hedge funds.

Senseonics Holdings, Inc. Common Stock Company Profile

Senseonics Holdings, Inc develops and commercializes long-term implantable continuous glucose monitoring (CGM) systems for people with diabetes. The company’s primary product family is the Eversense system, which combines a small subcutaneously implanted sensor, a removable external transmitter, and companion smartphone applications to provide continuous glucose readings and alerts. Senseonics positions its technology as an alternative to wearable patch-style CGMs by offering multi-month sensor longevity and on-body vibration alerts delivered through the transmitter.

Senseonics supports clinical and commercial activities that include research and development, regulatory engagement, manufacturing and distribution, and training for healthcare providers who perform sensor insertion and removal.